{
    "clinical_study": {
        "@rank": "114324", 
        "arm_group": [
            {
                "arm_group_label": "desloratadine (10 mg)", 
                "arm_group_type": "Experimental", 
                "description": "desloratadine 10 mg orally, once daily, two 5-mg tablets in the evening for 2 weeks"
            }, 
            {
                "arm_group_label": "desloratadine (5 mg)", 
                "arm_group_type": "Experimental", 
                "description": "desloratadine, 5 mg orally, once daily, one 5-mg tablet in the evening for 2 weeks"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matching placebo to desloratadine"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a study to evaluate the efficacy and safety of desloratadine in Japanese\n      participants with chronic urticaria."
        }, 
        "brief_title": "An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201)", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": "Urticaria", 
        "condition_browse": {
            "mesh_term": "Urticaria"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Chronic urticaria [rash (erythema, wheal) for more than 1 month without any known\n             cause]\n\n          -  Out-patient\n\n        Exclusion Criteria:\n\n          -  Stimulation-induced urticaria [physical urticaria (e.g. cold, solar, and heat\n             urticaria), cholinergic urticaria, contact urticaria)]\n\n          -  Hypersensitivity to antihistamines or ingredients of a study drug"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "239", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01916967", 
            "org_study_id": "4117-201", 
            "secondary_id": "MK-4117-201"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "desloratadine (10 mg)", 
                    "desloratadine (5 mg)"
                ], 
                "description": "desloratadine, oral administration in the evening, dosage form is a 5-mg tablet", 
                "intervention_name": "desloratadine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo given orally, once daily, as two 5-mg tablets in the evening", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Histamine Antagonists", 
                "Desloratadine", 
                "Histamine H1 Antagonists", 
                "Cholinergic Antagonists", 
                "Neurotransmitter Agents", 
                "Histamine H1 Antagonists, Non-Sedating"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Urticaria", 
            "Skin Diseases, Vascular", 
            "Skin Diseases", 
            "Hypersensitivity, Immediate", 
            "Hypersensitivity", 
            "Immune System Diseases", 
            "Cholinergic Antagonists", 
            "Cholinergic Agents", 
            "Neurotransmitter Agents", 
            "Histamine H1 Antagonists, Non-Sedating", 
            "Histamine H1 Antagonists", 
            "Histamine Antagonists", 
            "Histamine Agents"
        ], 
        "lastchanged_date": "March 27, 2014", 
        "number_of_arms": "3", 
        "official_title": "A Phase III Multicentre, Parallel-group, Randomized, Placebo-controlled, Double-blind Clinical Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Chronic Urticaria.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Change from baseline in sum score of pruritus/itch and rash assessed by  investigator at Week 2", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 2"
            }, 
            {
                "measure": "Percentage of participants who experienced at least one adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 4 weeks"
            }, 
            {
                "measure": "Percentage of participants who discontinued from study drug due to an adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 weeks"
            }
        ], 
        "removed_countries": {
            "country": "Japan"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01916967"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in sum score of pruritus/itch and rash assessed by investigator", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 3, and Week 1"
            }, 
            {
                "measure": "Change from baseline in pruritus/itch score assessed by investigator", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 3, Week 1, and Week 2"
            }, 
            {
                "measure": "Change from baseline in rash score assessed by investigator", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 3, Week 1, and Week 2"
            }, 
            {
                "measure": "Number of participants with a moderate or remarkable improvement in the Global Improvement Rate of both pruritus/itch and rash (erythema and wheal) assessed by investigator", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 3, Week 1, and Week 2"
            }, 
            {
                "measure": "Change from baseline in pruritus/itch score reported in participant's diary", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 3, Week 1, and Week 2"
            }, 
            {
                "measure": "Change from baseline in rash score reported in participant's diary", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 3, Week 1, and Week 2"
            }, 
            {
                "measure": "Change from baseline in the Dermatology Life Quality Index (DLQI) score recorded by participants", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 1, and Week 2"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}